SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported)      July 30, 2003

 

Specialty Laboratories, Inc.

(Exact name of registrant as specified in charter)

 

 

 

Registrant’s telephone number, including area code     (310) 828-6543

 

 

(Former name or former address, if changed since last report.)

 

 

ITEM 7					FINANCIAL STATEMENTS AND EXHIBITS
	(c)		Exhibits		The following document is filed as an exhibit to this report:
			99.1		Press Release dated July 30, 2003.

 

ITEM 9            REGULATION FD DISCLOSURE

 

This information is being furnished under Item 12 of Form 8-K and is being presented under Item 9 in accordance with the Securities and Exchange Commission’s interim guidance regarding Form 8-K Item 12 filing requirements, as set forth in Release No. 33-8216.

 

On July 30, 2003, Specialty Laboratories, Inc., (the “Registrant”) announced financial results for the second quarter ended June 30, 2003.  A copy of the press release issued by the Registrant on July 30, 2003 concerning the foregoing matter is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

 

2

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

		Specialty Laboratories, Inc.
Date:  July 30, 2003		By:	/s/ FRANK J. SPINA
			Frank J. Spina,
			Chief Financial Officer

 

3

 

EXHIBIT INDEX

 

		The following document is filed as an exhibit to this report:
Exhibits
99.1		Press Release dated July 30, 2003.

 

4